Internal Medicine

The baseline data for the initial 1000 participants recruited into the TX-YDSRN show 79.6% were diagnosed with a primary depressive disorder.

Investigators discuss the potential of psychedelic drugs as a new approach to treating mental illnesses, highlighting their therapeutic benefits and the need for further research to understand their effects, safety, and accessibility.

During the early pandemic period, video telehealth use increased among all veteran groups but differences were observed among American Indian/Alaska Native veterans.

Dr. Mikkael Sekeres discusses the approval of quizartinib (Vanflyta) and how it impacts the treatment of acute myeloid leukemia.

This approval is the first for an FLT3 inhibitor and it's specifically indicated for patients who have FLT3-ITD.

New cross-sectional data show the sex gap in alcohol-related mortality has been narrowing since 1999, as women have become more susceptible to alcohol use and related diseases.

An analysis of 7 international, longitudinal studies with nearly 20,000 patients details apparent increases in risk associated with daily alcohol consumption among healthy adults.

RiVive is the second nonprescription naloxone product approved by the FDA, signaling a proactive effort to increase accessibility and consumer availability of life-saving medication.

Using NHANES data, along with deidentified data from the Optum database, investigators estimate the prevalence of albuminuria testing among people with hypertension or diabetes as well as how the presence or lack of testing might influence prescription of CKD therapies.

The study presents a machine learning algorithm utilizing ECG data during CPAP titration that can effectively forecast sleep apnea events.

Certain craniofacial measurements identified by lateral cephalograms exhibit notable variations in patients with obstructive sleep apnea, providing potential indicators for early diagnosis.

Investigators aimed to support extending the US FDA labeling of Xembify to include the biweekly dosing option, therefore, providing greater flexibility and convenience for patients managing their immunodeficiencies.

The study suggests 1 in every 18 patients would need an MRI scan to detect such significant abnormalities.

Structural discrimination, such as sexism and racism, can exacerbate mental health challenges, leading to higher suicidal thoughts and behavior rates among multiple marginalized individuals.

Knowing how patients with different endotypes respond to CPAP therapy can help physicians predict treatment efficacy and tailor individualized treatment plans, according to results.

A systematic review of 55 studies conducted in the US and abroad details the effects of private equity ownership in health care settings on costs to patients/payers as well as clinical outcomes.

The AI chatbot, ChatGPT-4, responded correctly to 84% of multiple-choice practice questions on the OphthoQuestions trial, compared to 58% in February 2023.

Over 3 years, global health threats and national headlines have spurred medical schools to better address social and community-based determinants of health. What comes next?

Experts emphasize the fundamental principles of integrative care, the success seen in treating rare diseases, and how it can be applied to all chronic diseases.

Analysis results showed the differential impact of certain variables on the face inversion effect in individuals with autism spectrum disorder.

Efanesoctocog alfa defined a new therapy class by the US Food and Drug Administration (FDA) as the first and best-in-class high-sustained FVIII therapy.

Efanesoctocog alfa demonstrates promising results in new phase 3 data emphasizing the drug's potential to address unmet needs within the hemophilia community.

Informed discussions about the pros and cons of different treatments help guide the decision-making process. When it comes to treatment adherence and overall quality of life, patient lifestyle plays a significant role.

Dr. Juliana Biondo discusses what the future of treatment for hemophilia A looks like based on ongoing trials.

The American Indian and Alaska Native population show the largest increase in median state ratios, rising from 14 - 49.2, while the Black population consistently had the highest median state ratios, increasing from 26.7 - 55.4.

Dr. Juliana Biondo discusses the exciting FDA approval of Roctavian and how it compares with other treatment options like Hemlibra.

While the FDA decision of Roctavian offers patients with hemophilia A more options, the gene therapy eligibility criteria still pose barriers.

Despite concerns, Dr. Margaret Ragni discusses the significance of the Roctavian's effectiveness for reducing hemophilia A bleeds and improving patient quality of life.